Marcus M Reidenberg. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Cost-Benefit AnalysisDrugs, EssentialHumansOrphan Drug ProductionRare Diseases/drug therapyResource AllocationSocial JusticeWorld Health Organization
Substances: See more » Drugs, Essential
Year: 2006 PMID: 17128329 PMCID: PMC2627475 DOI: 10.2471/blt.06.0034447
Source DB: PubMed Journal: Bull World Health Organ ISSN: 0042-9686 Impact factor: 9.408